top of page
First in class novel inhibitors targeting a central pathway in fibrosis and inflammation
Inosi is developing therapies to address fibrosis, a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of organ function.
Inosi’s technology is based on collaborative research from the founding team at Monash University, the Monash Biomedicine Discovery Institute ,and the Monash Institute of Pharmaceutical Sciences.
​
IP Group helped spin-out the company and provided seed investment.
Our Partners
Fibrosis is a global problem with high unmet need
45%
deaths linked to fibrosis
10%
of the population have a fibrotic condition
0
drugs able to reverse fibrosis
bottom of page